Participant flow16

How many started, completed or left each group, period by period.

1 to 16 of 16

Period	Milestone	Group	Participants
Overall Study	STARTED	Liraglutide 0.6 mg	212
Overall Study	STARTED	Liraglutide 1.2 mg	209
Overall Study	STARTED	Liraglutide 1.8 mg	207
Overall Study	STARTED	Liraglutide Placebo	207
Overall Study	Exposed	Liraglutide 0.6 mg	211
Overall Study	Exposed	Liraglutide 1.2 mg	209
Overall Study	Exposed	Liraglutide 1.8 mg	206
Overall Study	Exposed	Liraglutide Placebo	206
Overall Study	COMPLETED	Liraglutide 0.6 mg	186
Overall Study	COMPLETED	Liraglutide 1.2 mg	177
Overall Study	COMPLETED	Liraglutide 1.8 mg	165
Overall Study	COMPLETED	Liraglutide Placebo	180
Overall Study	NOT COMPLETED	Liraglutide 0.6 mg	26
Overall Study	NOT COMPLETED	Liraglutide 1.2 mg	32
Overall Study	NOT COMPLETED	Liraglutide 1.8 mg	42
Overall Study	NOT COMPLETED	Liraglutide Placebo	27

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02098395/flow